Comparable stake leader
WELLINGTON MANAGEMENT GROUP LLP
SEC ownership of Heartflow, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001464521.
Disclosed value leader
WELLINGTON MANAGEMENT GROUP LLP
Comparable rows
50/50
Latest evidence
28 Apr 2026
- Public ticker
- HTFL on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
WELLINGTON MANAGEMENT GROUP LLP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
WELLINGTON MANAGEMENT GROUP LLP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
28 Apr 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001464521
- Issuer location
- San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Heartflow, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
WELLINGTON MANAGEMENT GRO...
Disclosed value leader
WELLINGTON MANAGEMENT GRO...
Comparable rows
50/50
Latest evidence
28 Apr 2026
13F
13D/G
3/4/5
Lead comparable stake: 14%
13D/G row: WELLINGTON MANAGEMENT GROUP LLP
Showing 1-8 of 50 holder rows.
Quick read
WELLINGTON MANAGEMENT GROUP LLP leads the comparable SEC ownership view at 14%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens WELLINGTON MANAGEMENT GROUP LLP's linked filing trail.
Comparable ownership
Top 5
WELLINGTON MANAGEMENT GROUP LLP
14%
BCLS Fund III Investments, LP
12%
Hayfin Special Opportunities Fund...
6.2%
FMR LLC
5.7%
HealthCor Partners Management LP
2.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
Company
|
14%
from 13D/G
|
$291,528,944
11,982,283 shares
|
— | 31 Mar 2026 |
| BCLS Fund III Investments, LP |
13D/G
3/4/5
10%+ Owner
|
12%
|
$282,936,119
10,448,158 shares
|
-$54,160,000 | 31 Mar 2026 |
| Hayfin Special Opportunities Fund II LP |
13D/G
Hayfin Management Holdings Limited
|
6.2%
|
$177,834,666
5,283,264 shares
|
$0 | 30 Sep 2025 |
| FMR LLC |
13D/G
13F
Company
|
5.7%
|
$159,219,679
4,730,234 shares
|
$0 | 30 Sep 2025 |
| HealthCor Partners Management LP |
13D/G
3/4/5
10%+ Owner
|
2.4%
|
$48,261,085
2,082,014 shares
|
-$106,988,264 | 24 Mar 2026 |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
Company · 10%+ Owner
|
9.8%
from 3/4/5
|
$254,203,684
10,448,158 shares
|
— | 31 Mar 2026 |
| Bain Capital Life Sciences Fund III, L.P. |
3/4/5
10%+ Owner
|
9.8%
|
$253,867,147
8,448,158 shares
|
-$58,898,336 | 28 Apr 2026 |
| Bain Capital Life Sciences III General Partner, LLC |
3/4/5
10%+ Owner
|
9.8%
|
$253,867,147
8,448,158 shares
|
-$58,898,336 | 28 Apr 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$359,507,435.
Buys
$1,053,680
Insiders: 1
Sells
$360,561,115
Insiders: 8
Net
-$359,507,435
Shares: -12,332,270
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 40,000
Shares: 12,372,270
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 10,115,805 | $0 | $298,017,328 | -$298,017,328 |
| 3-6 | 0 | 2,256,465 | $0 | $62,543,787 | -$62,543,787 |
| 6-9 | 40,000 | 0 | $1,053,680 | $0 | +$1,053,680 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Heartflow, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Bain Capital Life Sciences Investors, LLC
Net 12M change
-$359,507,432
Latest report
24 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 10%+ Owner | $253,867,147 | -$114,998,336 | -31% | Filing P/S | 28 Apr 2026 |
| BCLS Fund III Investments, LP | 10%+ Owner | $253,867,147 | -$58,898,336 | -19% | Filing P/S | 28 Apr 2026 |
| Bain Capital Life Sciences Fund III, L.P. | 10%+ Owner | $253,867,147 | -$58,898,336 | -19% | Filing P/S | 28 Apr 2026 |
| Bain Capital Life Sciences III General Partner, LLC | 10%+ Owner | $253,867,147 | -$58,898,336 | -19% | Filing P/S | 28 Apr 2026 |
| BCLS Fund III Investments GP, LLC | 10%+ Owner | $253,867,147 | -$58,898,336 | -19% | Filing P/S | 28 Apr 2026 |
| Jeffrey C. Lightcap | Director | $217,828,174 | +$1,053,680 | +0.49% | Mixed | 16 Jun 2026 |
| John C.m. Farquhar | Chief Executive Officer, Director | $16,027,725 | -$4,417,943 | -22% | Filing P/S | 24 Jun 2026 |
| Campbell Rogers | Chief Medical Officer | $5,699,810 | -$5,104,879 | -47% | Median | 15 Jun 2026 |
| Vikram Verghese | Chief Financial Officer | $5,130,077 | Median | 06 May 2026 | ||
| Timothy C. Barabe | Director | $4,037,427 | Mixed | 16 Jun 2026 | ||
| Marie L. Jones | Chief Accounting Officer | $756,249 | Median | 06 May 2026 | ||
| Julie A. Cullivan | Director | $682,275 | -$446,610 | -40% | Filing P/S | 16 Jun 2026 |
| HealthCor Partners Management LP | 10%+ Owner | $0 | Mixed | 11 Aug 2025 | ||
| William C. Weldon | Director | Mixed | 16 Jun 2026 | |||
| Casey M. Tansey | Director | Mixed | 16 Jun 2026 | |||
| Wayne Joseph Riley | Director | Mixed | 16 Jun 2026 | |||
| Nicholas Downing | Director | Mixed | 07 Aug 2025 |
Recent insider transactions for Heartflow, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| John C.m. Farquhar | HTFL | Common Stock | Sale | -7.83% | $1,361,500 | $35.00 | -38,900 | 457,935 | 24 Jun 2026 | Direct |
| William C. Weldon | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Timothy C. Barabe | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Julie A. Cullivan | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Jeffrey C. Lightcap | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Wayne Joseph Riley | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Casey M. Tansey | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Campbell Rogers | HTFL | Common Stock | Options Exercise | 12.7% | 10,000 | 88,731 | 15 Jun 2026 | Direct | ||
| Campbell Rogers | HTFL | Stock Option | Options Exercise | -12.2% | -10,000 | 71,633 | 15 Jun 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Sale | -4.34% | $643,017 | $28.50 | -22,562 | 496,835 | 10 Jun 2026 | Direct |
| Campbell Rogers | HTFL | Common Stock | Sale | -10.5% | $261,266 | $28.34 | -9,219 | 78,731 | 18 May 2026 | Direct |
| Campbell Rogers | HTFL | Common Stock | Options Exercise | 11.7% | 9,219 | 87,950 | 18 May 2026 | Direct | ||
| Campbell Rogers | HTFL | Stock Options | Options Exercise | -8.33% | -9,219 | 101,410 | 18 May 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Sale | -4.16% | $657,005 | $29.12 | -22,562 | 519,397 | 11 May 2026 | Direct |
| Marie L. Jones | HTFL | Common Stock. | Tax liability | -0.26% | -82 | 31,083 | 07 May 2026 | Direct | ||
| Campbell Rogers | HTFL | Common Stock | Tax liability | -0.8% | -637 | 78,731 | 07 May 2026 | Direct | ||
| Vikram Verghese | HTFL | Common Stock. | Tax liability | -0.22% | -473 | 210,854 | 07 May 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Tax liability | -0.35% | -1,904 | 541,959 | 07 May 2026 | Direct | ||
| Marie L. Jones | HTFL | Common Stock. | Tax liability | -1.53% | -485 | 31,165 | 06 May 2026 | Direct | ||
| Campbell Rogers | HTFL | Common Stock | Tax liability | -2.02% | -1,634 | 79,368 | 06 May 2026 | Direct | ||
| Vikram Verghese | HTFL | Common Stock. | Tax liability | -0.72% | -1,536 | 211,327 | 06 May 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Tax liability | -0.97% | -5,300 | 543,863 | 06 May 2026 | Direct | ||
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -10.1% | $27,733,644 | $29.23 | -948,757 | 8,448,158 | 30 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -10.1% | $27,733,644 | $29.23 | -948,757 | 8,448,158 | 30 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -10.1% | $27,733,644 | $29.23 | -948,757 | 8,448,158 | 30 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -10.1% | $27,733,644 | $29.23 | -948,757 | 8,448,158 | 30 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -10.1% | $27,733,644 | $29.23 | -948,757 | 8,448,158 | 30 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -7.82% | $23,411,796 | $29.37 | -797,133 | 9,396,915 | 29 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -7.82% | $23,411,796 | $29.37 | -797,133 | 9,396,915 | 29 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -7.82% | $23,411,796 | $29.37 | -797,133 | 9,396,915 | 29 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -7.82% | $23,411,796 | $29.37 | -797,133 | 9,396,915 | 29 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -7.82% | $23,411,796 | $29.37 | -797,133 | 9,396,915 | 29 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -2.43% | $7,752,896 | $30.51 | -254,110 | 10,194,048 | 28 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -2.43% | $7,752,896 | $30.51 | -254,110 | 10,194,048 | 28 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -2.43% | $7,752,896 | $30.51 | -254,110 | 10,194,048 | 28 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -2.43% | $7,752,896 | $30.51 | -254,110 | 10,194,048 | 28 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -2.43% | $7,752,896 | $30.51 | -254,110 | 10,194,048 | 28 Apr 2026 | See footnotes |
| John C.m. Farquhar | HTFL | Common Stock | Sale | -3.95% | $602,857 | $26.72 | -22,562 | 549,163 | 10 Apr 2026 | Direct |
| Campbell Rogers | HTFL | Common Stock | Sale | -44.3% | $1,590,093 | $24.64 | -64,533 | 81,002 | 01 Apr 2026 | Direct |
| Campbell Rogers | HTFL | Common Stock | Options Exercise | 85.4% | 67,017 | 145,535 | 01 Apr 2026 | Direct | ||
| Campbell Rogers | HTFL | Stock Option | Options Exercise | -94.8% | -60,168 | 3,298 | 01 Apr 2026 | Direct | ||
| Campbell Rogers | HTFL | Stock Options | Options Exercise | -100% | -6,849 | 0 | 01 Apr 2026 | Direct | ||
| Jeffrey C. Lightcap | HTFL | Common Stock | Other | 515.6% | 206,261 | 246,261 | 24 Mar 2026 | Direct | ||
| HealthCor Partners Management LP | HTFL | COMMON STOCK | Other | -100% | -4,615,542 | 0 | 24 Mar 2026 | By HCPCIV I, LLC | ||
| Campbell Rogers | HTFL | Common Stock | Sale | -45.1% | $1,658,033 | $25.69 | -64,533 | 78,518 | 19 Mar 2026 | Direct |
| Campbell Rogers | HTFL | Common Stock | Options Exercise | 88.1% | 67,017 | 143,051 | 19 Mar 2026 | Direct | ||
| Campbell Rogers | HTFL | Stock Option | Options Exercise | -32.1% | -67,017 | 141,510 | 19 Mar 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Sale | -1.67% | $243,125 | $25.00 | -9,725 | 571,725 | 18 Mar 2026 | Direct |
| Timothy C. Barabe | HTFL | Common Stock | Options Exercise | 5.07% | 8,667 | 179,521 | 11 Mar 2026 | Direct | ||
| Timothy C. Barabe | HTFL | Stock Option | Options Exercise | -36% | -8,667 | 15,412 | 11 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.